ReviewCancer cell international2026
Mechanism of detection Gastrointestinal cancer using biosensors based on non-coding RNA.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) cancers represent a significant public health concern, characterized by substantial morbidity and mortality rates. Early and accurate diagnosis is crucial in enhancingpatient outcomes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are key players in cancer development and progression. Their distinct expression profiles in cancer tissues and body fluids make them promising biomarkers for GI cancer diagnosis. This review investigates the diverse types of ncRNAs and their roles in GI cancer. Additionally, we explorevarious biosensor technologies employed for ncRNA detection, including electrochemical, optical, and photoelectrochemical methods. Compared to traditional diagnostic approaches, these biosensors offer advantages such as high sensitivity, specificity, and rapid detection times. Recent advancements in ncRNA biosensor design, such as signal amplification strategies to improve detection limits, the challenges of ncRNA biosensor development, including complex sample matrices and the need for further clinical validation are also highlighted. Overall, ncRNA biosensors hold great promise for the early and accurate diagnosis of GI cancers. Continued research and development are necessary to translate these technologies into clinical practice and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.